The Front Room — a clinical regulatory commons
RSS
← Back to feed

Bimatoprost grenod NDA accepted for glaucoma, OHT

Drug
bimatoprost grenod
Indication
open-angle glaucoma and ocular hypertension

FDA accepted a New Drug Application for bimatoprost grenod for the treatment of open-angle glaucoma and ocular hypertension.

What this means

Bimatoprost grenod is an eye drop that lowers high pressure inside the eye, a condition that can lead to glaucoma. The FDA has accepted a new drug application to review this treatment for open-angle glaucoma and ocular hypertension. If approved, it would provide a new option for patients who need to control their eye pressure to prevent vision loss.

Read original at news.google.com ↗
Topic NDA acceptance